Annals of internal medicine · 2008
Human papillomavirus infection and cervical cytology in women screened for cervical cancer in the United States, 2003-2005.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Datta S Deblina, Koutsky Laura A, Ratelle Sylvie, Unger Elizabeth R, Shlay Judith, McClain Tracie, Weaver Beth, Kerndt Peter, Zenilman Jonathan, Hagensee Michael, Suhr Cristen J, Weinstock Hillard
Аннотация
BACKGROUND: Millions of women in the United States receive cervical screening in sexually transmitted disease (STD), family planning, and primary care clinical settings.
OBJECTIVE: To inform current cervical screening programs.
DESIGN: Measurement of abnormal Papanicolaou (Pap) tests and high-risk human papillomavirus (HPV) infection among demographically diverse women who received routine cervical screening from January 2003 to December 2005 in the United States.
SETTING: 26 STD, family planning, and primary care clinics in 6 U.S. cities.
PATIENTS: 9657 women age 14 to 65 years receiving routine cervical screening.
MEASUREMENTS: Pap test results and high-risk HPV prevalence by Hybrid Capture 2 assay (Digene, Gaithersburg, Maryland).
RESULTS: Among 9657 patients, overall high-risk HPV prevalence by Hybrid Capture 2 testing was 23% (95% CI, 22% to 24%). Prevalence was highest among women age 14 to 19 years (35% [CI, 32% to 38%]) and lowest among women age 50 to 65 years (6% [CI, 4% to 8%]). Prevalence by clinic type (adjusted for age and city) ranged from 26% (CI, 24% to 29%) in STD clinics to 17% (CI, 16% to 20%) in primary care clinics. Women younger than 30 years of age whose Pap test showed atypical squamous cells of undetermined significance had a high-risk HPV prevalence of 53%; women 30 years of age or older with normal Pap tests had a 9% prevalence. Values did not vary substantially by clinic type.
LIMITATION: Hybrid Capture 2 and Pap testing were noncentralized, and consent was required for enrollment.
CONCLUSION: High-risk HPV was widespread among women receiving cervical screening in the United States. Many women 30 years of age or older with normal Pap tests would need follow-up if Hybrid Capture 2 testing is added to cytology screening.
OBJECTIVE: To inform current cervical screening programs.
DESIGN: Measurement of abnormal Papanicolaou (Pap) tests and high-risk human papillomavirus (HPV) infection among demographically diverse women who received routine cervical screening from January 2003 to December 2005 in the United States.
SETTING: 26 STD, family planning, and primary care clinics in 6 U.S. cities.
PATIENTS: 9657 women age 14 to 65 years receiving routine cervical screening.
MEASUREMENTS: Pap test results and high-risk HPV prevalence by Hybrid Capture 2 assay (Digene, Gaithersburg, Maryland).
RESULTS: Among 9657 patients, overall high-risk HPV prevalence by Hybrid Capture 2 testing was 23% (95% CI, 22% to 24%). Prevalence was highest among women age 14 to 19 years (35% [CI, 32% to 38%]) and lowest among women age 50 to 65 years (6% [CI, 4% to 8%]). Prevalence by clinic type (adjusted for age and city) ranged from 26% (CI, 24% to 29%) in STD clinics to 17% (CI, 16% to 20%) in primary care clinics. Women younger than 30 years of age whose Pap test showed atypical squamous cells of undetermined significance had a high-risk HPV prevalence of 53%; women 30 years of age or older with normal Pap tests had a 9% prevalence. Values did not vary substantially by clinic type.
LIMITATION: Hybrid Capture 2 and Pap testing were noncentralized, and consent was required for enrollment.
CONCLUSION: High-risk HPV was widespread among women receiving cervical screening in the United States. Many women 30 years of age or older with normal Pap tests would need follow-up if Hybrid Capture 2 testing is added to cytology screening.